Improving clinical descriptions to understand the effects of dementia treatment: Consensus recommendations

International Journal of Geriatric Psychiatry

Volumn 17, Issue 11, 2002, Pages 1006-1011

  Rockwood, Kenneth ^a,b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b Geriatric Medicine Research Unit Capital Health   (Canada)

Author keywords

Alzheimer's disease; Cholinestrase inhibitors; Individualized outcome measures; Qualitative studies; Quality of life

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; METRIFONATE;

ALZHEIMER DISEASE; BRAIN; CAREGIVER; CHOLINERGIC SYSTEM; CLINICAL OBSERVATION; CLINICAL TRIAL; CLINICIAN'S INTERVIEW BASED IMPRESSION OF CHANGE; COGNITIVE DEFECT; DEMENTIA; DRUG EFFECT; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FUNCTIONAL ASSESSMENT; HUMAN; INTERVIEW; MEDICAL DECISION MAKING; PATIENT CARE; PATIENT SELECTION; PROSPECTIVE STUDY; QUALITATIVE ANALYSIS; QUESTIONNAIRE; REVIEW; SCORING SYSTEM; TREATMENT OUTCOME;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS; HUMANS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0036850844     PISSN: 08856230     EISSN: None     Source Type: Journal    
DOI: 10.1002/gps.733     Document Type: Review

References (38)

1. Birks JS, Melzer D. 2000. Donepezil for mild and moderate Alzheimer's disease. Cochrane Database Syst Rev 2: CD001190.
2. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. 2000. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 4: CD001191.
3. Bogardus ST, Jr, Bradley EH, Tinetti ME. 1998. A taxonomy for goal setting in the care of persons with dementia. J Gen Int Med 14: 675-680.
4. Bogardus ST, Bradley EH, Williams CS, Maciejewski PK, van Doorn C, Inouye SK. 2001. Goals for the care of frail older adults: do caregivers and clinicians agree? Am J Med 110: 97-102.
5. Bradley EH, Bogardus ST, Jr, Tinetti ME, Inouye SK. 1999. Goal-setting in clinical medicine. Soc Sci Med 49: 267-278.
6. Cummings JL, Mega M, Gray K, Rosenburg-Thompson S, Carusi DA, Gornbein J. 1994. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44: 2308-2314.
7. Dastoor DP, Cole MG. 1986. The course of Alzheimer's disease: an uncontrolled longitudinal study. J Clin Exp Gerontol 7: 289-299.
8. Feinstien AR. 1994. 'Clinical Judgement' revisited: the distraction of quantitative models. Ann Intern Med 120: 799-805.
9. Feldman H, Sauter A, Donald A, et al. 2001. The disability assessment for dementia scale: a 12-month study of functional ability in mild to moderate severity Alzheimer disease. Alzheimer Dis Assoc Disord 15: 89-95.
10. Folstein MF, Folstein S, McHugh PR. 1975. 'Mini-Mental state': a practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 12: 189-198.
11. Geldmacher DS. 1997. Clinical experience with donepezil hydrochloride: a case study perspective. Advances Therapy 14: 305-311.
12. Gelinas I, Gauthier L, McIntyre M, Gauthier S. 1999. Development of functional disability measure for persons with Alzheimer's disease: the Disability Assessment for Dementia. Am J Occup Ther 53: 471-481.
13. Gordon J, Powell C, Rockwood K. 1997. Goal attainment scaling as an outcome measure in long term care. Clin Invest Med 20: S27.
14. Ham RJ. 1997. Clinical efficacy of donepezil hydrochloride in patients with Alzheimer's disease: case studies. Advances Therapy 14: 223-233.
15. Hartman D, Borrie MJ, Davison E, Stolee P. 1997. Use of goal attainment scaling in a dementia special care unit. Am J Alz Dis 12: 111-116.
16. Harvey R. 1999. A Review and Commentary on a Sample of 15 UK Guidelines for the Drug Treatment of Alzheimer Disease. Int J Geriatr Psychiatry 14: 249-256.
17. Joffres C, Graham JE, Rockwood K. 2000. A Qualitative Analysis of The Clinician Interview-Based Impression of Change (Plus): Methodological Issues and Implications for Clinical Research. Int Psychogeriatr 12: 403-413.
18. Joffres C, Bucks RS, Haworth J, Wilcock GK, Rockwood K. Patterns of clinically detectable treatment effects with galantamine: a qualitative analysis. Dement Geriatr Cogn Disord (in press).
19. Knopman DS, Knapp MJ, Gracon SI, Davis CS. 1994. The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology 44: 2315-2321.
20. Knopman DS. 1998. Clobal change assessments in anti-Alzheimer clinical drug trials. Dement Geriatr Cogn Disord 9(Suppl.3): 8-15.
21. Livingstone G, Katona C. 2000. How useful are cholinesterase inhibitors in the treatment of Alzheimer's disease? A number needed to treat analysis. Int J Geriatr Psychiatry 15: 203-207.
22. Leber PD. 1997. Developing safe and effective antidementia drugs. In Alzheimer Disease: From Molecular Biology to Therapy, Becker R, Giacobini E (eds). Birkhauser: Boston; 579-584.
23. Lovestone S, Murray D. 2001. Acetylcholinesterase treatment - modelling potential demand and auditing practice. Int J Geriatr Psychiatry 16: 1136-1142.
24. Morris JC. 1993. The Clinical Dementia Rating (CDR): current version and scoring rules. J Am Geriatr Soc 43: 2412-2414.
25. Olin JT, Schneider LS, Doody RS, et al. 1996. Clinical evaluation of global change in Alzheimer's disease: identifying consensus. J Geriatr Psychiatr Neurol 9: 176-180.
26. Olin JT, Schneider LS. 2001. Galantamine for Alzheimer's disease (Cochrane Review). Cochrane Database Syst Rev 4: CD001747.
27. Reisberg B, Ferris SH, de Leon MJ, Crook T. 1982. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 139: 1136-1142.
28. Reisberg B, Schenck MK, Ferris SH, et al. 1983. The Brief Cognitive Rating Scale: Findings in primary degenerative dementia. Psychopharmacol Bull 19: 47-50.
29. Rockwood K. 1994. Use of global assessment measures in dementia drug trials. J Clin Epidemiol 47: 101-103.
30. Rockwood K, Stolee P, Howard K, Mallery L. 1996. Use of Goal Attainment Scaling to measure treatment effects in an anti-dementia drug trial. Neuroepidemiol 15: 330-338.
31. Rockwood K, Strang D, MacKnight C, Downer R, Morris JC. 2000. Inter-rater reliability of the Clinical Dementia Rating in a multicenter trial. J Am Geriatr Soc 48: 558-559.
32. Rockwood K, Stolee P. 2000. Responsiveness of outcome measures used in an antidementia drug trial. Alz Dis Assoc Disord 4: 182-185.
33. Rockwood K, MacKnight C. 2001. Assessing the clinical importance of statistically significant improvement in anti-dementia drug trials. Neuroepidemiol 20: 51-56.
34. Schneider LS, Olin JT. 1996. Clinical global impression of change: clinical global impression of change in Alzheimer's clinical trials. Int Psychogeriatr 8: 277-290.
35. Shua-Haim JR, Comsti E, Shua-Haim V, Ross JS. 1997. Donepezil Aricept (TM): the caregivers voice and clinical impression. Am J Alz Dis 12: 272-279.
36. Stolee P, Zaza C, Pedlar A, Myers AM. 1999. Clinical experience with Goal Attainment Scaling in geriatric care. J Aging Health 11: 96-124.
37. Swanwick GR, Lawlor BA. 1999. Initiating and monitoring cholinesterase inhibitor treatment for Alzheimer's disease. Int J Geriatr Psychiatry 14: 244-248.
38. Winblad B, Brodaty H, Gauthier S, et al. 2001. Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success? Int J Geriatr Psychiatry 16: 653-666.